TAUGHT SESSIONSThis 2-day course shows you how to detect, reduce and characterise unwanted immunogenicity
INTERACTIVE TASKSDiscuss the advantages/disadvantages of various assay platforms used to detect and characterise unwanted immunogenicity
CASE STUDIES...and interactive sessions to provide hands-on experience
Assay development – practical aspects using ELISA as an example
Early detection of immunogenicity reactions is a key component of a drug development programme.
This 2-day course shows you how to detect, reduce and characterise unwanted immunogenicity, interpret the latest EMA and FDA regulatory guidelines and formulate a winning strategy that you can implement into your business immediately.
Most of the sessions comprise a formal presentation followed by facilitated break-out groups where delegates will be given the opportunity to apply some of the principles from the taught sections. The break-out sessions will be fully supported with background documentation and experts will be available to facilitate and guide the groups during these sessions.
Those working in:
• Biotech R&D Staff
• Bioanalytical Scientists
• Clinical Research Associates
• Validation Specialists
• Project Management
• Regulatory Affairs
Connect with the PTI faculty! PTI is a global pharmaceutical training company with over 60 interctive courses focusing on Regulatory Affairs, R&D, Clinical, Business Strategy, Fine Chemicals, Biopharmaceuticals, Manufacturing, Medical Devices and Agrochemicals